Aytu BioPharma Inc. Common Stock (AYTU)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham-minded investor, I start with durable earning power. Aytu sells specialty prescription medicines, mainly ADHD products, with 75 employees. In fiscal 2026, the year ended 2026-06-30, it reported revenue of $57.6 million and a net loss of $14.3 million, or diluted EPS of -$1.16. That followed fiscal 2025 revenue of $66.4 million and a net loss of $13.6 million, and fiscal 2024 revenue of $65.2 million and a net loss of $15.8 million. The top line is shrinking and losses persist, so I see no clear moat. The balance-sheet and return picture is mixed: at the 2026-10-13 close of $1.99, FairStock calculations put P/B at 0.61, P/E negative, ROE at -97.42%, ROCE at -3.65%, and D/E at 0.65. FairStock's Piotroski F-Score of 8/9 is a positive sign, but its Altman Z-Score of -4.24 warns of financial distress. Trailing free cash flow of $3.3 million gives a 15.0% FCF yield on a $21.6 million market cap, which is attractive if it lasts. Yet the company has lost money in each of the last four years, and FairStock assigns no Lynch category for that reason. Graham would call the asset discount interesting only with a margin of safety; Buffett would want proven, consistent profits. At this price, the market is pricing doubt, and the numbers justify caution until revenue stabilizes and net income turns reliably positive.

In plain English: Aytu BioPharma sells prescription medicines, mostly for ADHD, in the United States and abroad. The business looks weak because it has lost money in recent years, including a $14.3 million loss in the fiscal year ended 2026-06-30, and revenue has shrunk. At its 2026-10-13 close of $1.99, the stock looks inexpensive compared with its accounting value and cash flow, but the losses mean it is not clearly cheap or safe.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer